| Literature DB >> 32991858 |
Muzna Hussain1, Yuan Hou2, Chris Watson3, Rohit Moudgil4, Chirag Shah5, Jame Abraham6, G Thomas Budd6, W H Wilson Tang4, J Emanuel Finet4, Karen James4, Jerry D Estep4, Bo Xu4, Bo Hu7, Paul Cremer4, Christine Jellis4, Richard A Grimm4, Neil Greenberg4, Zoran B Popovic4, Leslie Cho4, Milind Y Desai4, Steven E Nissen4, Samir R Kapadia4, Lars G Svensson8, Brian P Griffin4, Feixiong Cheng9, Patrick Collier10.
Abstract
To evaluate the temporal relations of cardiovascular disease in oncology patients referred to cardio-oncology and describe the impact of cardiovascular disease and cardiovascular risk factors on outcomes. All adult oncology patients referred to the cardio-oncology service at the Cleveland Clinic from January 2011 to June 2018 were included in the study. Comprehensive clinical information were collected. The impact on survival of temporal trends of cardiovascular disease in oncology patients were assessed with a Cox proportional hazards model and time-varying covariate adjustment for confounders. In total, 6,754 patients were included in the study (median age, 57 years; [interquartile range, 47 to 65 years]; 3,898 women [58%]; oncology history [60% - breast cancer, lymphoma, and leukemia]). Mortality and diagnosis of clinical cardiac disease peaked around the time of chemotherapy. 2,293 patients (34%) were diagnosed with a new cardiovascular risk factor after chemotherapy, over half of which were identified in the first year after cancer diagnosis. Patients with preexisting and post-chemotherapy cardiovascular disease had significantly worse outcomes than patients that did not develop any cardiovascular disease (p < 0.0001). The highest 1-year hazard ratios (HR) of post-chemotherapy cardiovascular disease were significantly associated with male (HR 1.81; 95% confidence interval 1.55 to 2.11; p < 0.001] and diabetes [HR 1.51; 95% confidence interval 1.26 to 1.81; p < 0.001]. In conclusion, patients referred to cardio-oncology, first diagnosis of cardiac events peaked around the time of chemotherapy. Those with preexisting or post-chemotherapy cardiovascular disease had worse survival. In addition to a high rate of cardiovascular risk factors at baseline, risk factor profile worsened over course of follow-up.Entities:
Mesh:
Year: 2020 PMID: 32991858 PMCID: PMC7704696 DOI: 10.1016/j.amjcard.2020.09.030
Source DB: PubMed Journal: Am J Cardiol ISSN: 0002-9149 Impact factor: 2.778